



The cascade of care for children and adolescents with HIV in the UK and Ireland in 2015

Jeannie Collins*, Elizabeth Chappell, Helen Peters, Kate Francis, Siobhan Crichton, Claire Thorne and Ali Judd on behalf of the National Study of HIV in Pregnancy and Childhood (NSHPC) and the Collaborative HIV Paediatric Study (CHIPS)

*MRC Clinical Trials Unit at University College London (UCL)

UNAIDS target for 2020

THE TREATMENT TARGET

90%


diagnosed

90%

on treatment


90%

virally suppressed




Cascade of care: 90-90-90 targets for 2020

- 90% of individuals with HIV know their status
- 90% of those diagnosed on antiretroviral treatment (ART)
- 90% of those on treatment are virally suppressed




Cascade of care: 90-90-90 targets for 2020

- Global cascade estimates for 2016¹:
 - 90% of individuals with HIV know their status: **70%**
 - 90% of those diagnosed on ART: **77%**
 - 90% of those on treatment virally suppressed: **82%**






UK HIV continuum of care: progress against UNAIDS targets






ART coverage and VL suppression among heterosexual Black African women by age group: United Kingdom 2014



VL suppression: having the most recent VL undetectable (VL<200 copies/ml)



ART coverage and VL suppression among heterosexual Black African women by age group: United Kingdom 2014



VL suppression: having the most recent VL undetectable (VL<200 copies/ml)

CHIPS: national cohort of patients in paediatric HIV care in UK & Ireland

Paediatric HIV Clinic: annual follow-up form



2133 ever in CHIPS

Half transferred to adult care



<http://www.chipscohort.ac.uk>

Adapted Cascade of Care in 2015

Design: Cross sectional approach using longitudinal data

Inclusion criteria: age <21 years and not known to have died, left the country, transferred to adult care or lost-to-follow-up as of 1st Jan 2015.

We describe :


- Among those diagnosed, % in active care (≥ 1 record of clinic visit)
- Among those in active care, % on any ART at last visit
- Among those on ART, % virally suppressed ($VL \leq 400$ copies/mL) at last visit
- Among those on ART, % with good immune status at last visit*

*WHO 2007 immune stage none/mild: $CD4 > 30\%$ for <1 yr, $CD4 > 25\%$ for 1-3 yrs, $CD4 > 20\%$ for 3-5 yrs, $CD4 > 350$ cells/mm³ for ≥ 5 yrs.

Characteristics of patients on follow up in 2015


	Overall (N=984) n (%) or median [IQR]
Female	520 (53%)
Born abroad	512 (52%)
Previously diagnosed abroad	138 (27%)
Age at diagnosis in UK, years	3.7 [0.9, 7.7]
Mode of infection: vertical	937 (97%)

Cascade of care in paediatric HIV 2015



Cascade of care in paediatric HIV 2015

Median CD4 714 cells
[IQR, 540-974]
among >5yrs




■ <5 years (n=35; 4%)

■ 5-<10 years (n=151; 15%)

■ 10-<15 years (n=402; 41%)

■ ≥15 years (n=396; 40%)




■ <5 years (n=35; 4%)

■ 5-<10 years (n=151; 15%)

■ 10-<15 years (n=402; 41%)

■ ≥15 years (n=396; 40%)



- No effect of sex
- Patients born abroad were less likely to be in active care (93% vs 97%, p=0.002), and less likely to be virologically suppressed on ART (85% vs 91%, p=0.007)

Conclusions

- In 2015, 87% of all children/adolescents diagnosed with HIV in the UK/Ireland were on ART and 91% of those on ART were virologically suppressed
- Some variation by age group and place of birth; those ≥ 15 years and those born abroad had slightly poorer outcomes, though generally still above 90%
- Limitations: difficult to estimate number living with HIV
- Ongoing work on cascade of care post-transfer to adult care

UPDATE: Extending CHIPS to CHIPS+

Aims:

- To establish a paediatric-adult cohort study of perinatally HIV infected patients ever followed in CHIPS → CHIPS+
 - Assess long term outcomes through adulthood
 - Annual follow up form: CD4, VL, ART history, hospitalisation, pregnancy, CDC stage, serious non AIDS events
 - Inclusion criteria: Age ≥ 15 years; ever received HIV care in a paediatric clinic in the UK/Ireland
 - Requires consent at age ≥ 15 years
- >> Ethics approval in the UK, in process for Ireland

Moving on to CHIPS+

Paediatric HIV Clinic

Adult HIV Clinic

Adolescent HIV Clinic


Data linkage :

- PHE
- NHS Digital

Consent

CHIPS: Annual follow up paediatric care

CHIPS+ : Continue follow up in adult care



Moving on to CHIPS+

Paediatric HIV Clinic

Adult HIV Clinic

Adolescent HIV Clinic

Data linkage :
• PHE
• NHS Digital

- 7 clinics open, further 12 UK clinics have R&D approval
- Kate Sturgeon is contacting/visiting clinics
- For information contact: <mrcttu.chipsplus@ucl.ac.uk>

Consent

CHIPS: Annual follow up paediatric care

CHIPS+ : Continue follow up in adult care

Acknowledgements

- All contributing clinics and patients
- NSHPC and CHIPS Steering Committees
- **Funding:** NHS England (London Specialised Commissioning Group) and has received additional support from the PENTA Foundation as well as Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, and ViiV Healthcare. This work was supported by the MRC programme grant MC_UU_12023/26.